Value and income investing. Long-term capital appreciation.
The aggressive large cap growth stocks that have been dominating the market this year (e.g. Facebook, Amazon, Netflix and Google/Alphabet) have recently been showing signs of capitulation. Rather than chasing after the most popular growth stocks, this article highlights 10 big safe income-generating investment opportunities that we believe are worth considering.
Interested in a Free Investment Portfolio Review?
Blue Harbinger’s Mark D. Hines works with Left Brain Wealth Management to provide custom investment advisory services to meet your individual needs. Contact us today to schedule your complimentary investment portfolio review.
Curious what your investment risk tolerance really is? Complete our 10-minute Risk Questionnaire and instantly receive your risk score.
Members-Only Investment Ideas
If you are an income-focused investor, and you occassionally like to take on more aggressive trading opportunities, we have an interesting idea for you that we believe is worth considering.
Income investors love to own big dividend stocks, but sometimes it’s worthwhile to diversify into companies with smaller albeit growing dividends that also offer significant price appreciation potential. This article reviews one such opportunity that we believe has the opportunity to grow dramatically over time both its dividend and especially its price.
As we've written before, there is a false narrative going around, and it has created an attractive investment opportunity in this big-dividend blue chip stock. And in our view, selling put options on it is particularly attractive right now.
There was an interesting Warren Buffett interview last week where the “Oracle of Omaha” gave a handful of very wise advice to investors. However, we couldn’t help but notice, he seemed to make a glaring fundamental mistake. This article reviews Buffett’s good advice, postulates a couple reasons why he could have made his glaring fundamental mistake, and we finally offer a smart way (a specific security) to take advantage of Buffett’s good advice without making the same big mistake.
There’s a false narrative going around, and it has created an attractive investment opportunity in this big-dividend blue chip stock.
This report is a continuation of our free public report titled "Top 7 High-Yield Healthcare REITs Worth Considering." However, this members-only report contains the top 3...
The Blue Harbinger Weekly:
A members-only weekly report on Blue Harbinger's investments and the market.
It may seem counterintuitive, but we just sold one of our top-performing Dividend Aristocrats, and we used the proceeds to buy a “Dog of the Dow” that is currently hated by the market. And as contrarians, we wouldn’t have it any other way.
All Blue Harbinger strategies continue to deliver strong positive returns without any of the full-service brokerage fees that “do-it-yourself investors” are trying to avoid. Our Disciplined Growth portfolio beat the S&P 500 during May, and our Income Equity strategy finished the month with a 5.4% yield, nearly 3.5% higher than the S&P 500. We’ve seen value stocks underperform growth stocks this year, and as contrarians we like value stocks even more now.
As a follow up to our free article titled “10 Attractive High-Yield Blue Chips, For Contrarians,” this members-only article highlights five more attractive opportunities. And in this case, we currently own all five of these investments.
The Dogs of the Dow strategy proposes that an investor invests annually in the ten Dow Jones stocks with the highest dividend yield. Proponents of the strategy argue that blue-chip companies do not alter their dividend to reflect trading conditions and, therefore, the dividend is a measure of the average worth of the company. The following table ranks the 30 Dow Jones stocks by dividend yield, it includes a variety of other financial metrics, and finally we discuss two of our favorite Dogs of the Dow right now.
This week’s Weekly reviews an attractive +7% yield MLP that is on sale. We also review two growth stocks that we own in our Disciplined Growth portfolio. The MLP is very hated (and misunderstood) right now (which is why we like it), and the growth stocks have both rallied hard this year (they’re up 30% and 47%) and we share our views on how to play them going forward.
This week’s Weekly provides a brief review of every Blue Harbinger holding, including comments, year-to-date price returns and year-to-date total returns (dividends plus price appreciation). We also share market-wide data on what has been working, and what we expect will work going forward.